Cyclacel Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Cyclacel Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 21, 2024, to vote on director re-elections, auditor ratification, and equity plan amendments.</b>

AI Summary

Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Proxy Statement (DEF 14A) with the SEC on May 8, 2024. The 2024 Annual Meeting of Stockholders for Cyclacel Pharmaceuticals, Inc. will be held on June 21, 2024, at 11:00 a.m. EDT. The meeting will be conducted virtually via live audio webcast on the internet at www.virtualshareholdermeeting.com/CYCC2024. Stockholders will be asked to re-elect three Class 3 directors: Dr. Christopher Henney, Paul McBarron, and Dr. Robert Spiegel. The appointment of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, will be ratified. An amendment to the 2018 Equity Incentive Plan to increase the number of shares available for awards by 160,000 shares will be proposed for approval.

Why It Matters

For investors and stakeholders tracking Cyclacel Pharmaceuticals, Inc., this filing contains several important signals. The shift to a virtual meeting format aims to increase stockholder attendance and participation globally, while also improving efficiency and reducing costs. Key proposals include the re-election of directors and an amendment to the equity incentive plan, which could impact future share dilution and executive compensation.

Risk Assessment

Risk Level: low — Cyclacel Pharmaceuticals, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting with standard proposals, indicating no immediate significant financial or operational shifts.

Analyst Insight

Stockholders should review the proposals regarding director re-elections and the equity incentive plan amendment to make informed voting decisions.

Key Numbers

• June 21, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders.)
• 11:00 a.m. EDT — Meeting Time (Time of the 2024 Annual Meeting of Stockholders.)
• 160,000 — Additional Shares (Increase in shares available under the 2018 Equity Incentive Plan.)
• 2024 — Fiscal Year End (Fiscal year for which RSM US LLP is proposed as auditor.)

Key Players & Entities

• Cyclacel Pharmaceuticals, Inc. (company) — Registrant and filer of the proxy statement.
• Dr. Christopher Henney (person) — Nominee for Class 3 director.
• Paul McBarron (person) — Nominee for Class 3 director.
• Dr. Robert Spiegel (person) — Nominee for Class 3 director.
• RSM US LLP (company) — Proposed independent registered public accounting firm.
• 2018 Equity Incentive Plan (company) — Plan proposed for amendment.
• June 21, 2024 (date) — Date of the Annual Meeting of Stockholders.
• 160,000 (dollar_amount) — Number of additional shares to be made available under the equity incentive plan.

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
• Equity Incentive Plan Amendment [medium — financial]: Approval of the amendment to the 2018 Equity Incentive Plan could result in the issuance of additional shares, potentially diluting existing stockholders.
• Virtual Meeting Format [low — operational]: Reliance on a virtual format for the annual meeting may present technical challenges for some stockholders or limit direct interaction.

Key Dates

• 2024-06-21: Annual Meeting of Stockholders — Key date for voting on director re-elections, auditor ratification, and equity plan amendments.

Filing Documents

• tm242764-1_def14a.htm (DEF 14A) — 730KB
• bc_paidvsnetloss-4c.jpg (GRAPHIC) — 62KB
• bc_paidvstsr-4c.jpg (GRAPHIC) — 51KB
• px_24cyclacelpxy1pg01-bw.jpg (GRAPHIC) — 238KB
• px_24cyclacelpxy1pg02-bw.jpg (GRAPHIC) — 219KB
• 0001104659-24-058318.txt (&nbsp;) — 1453KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 8 MANAGEMENT AND CORPORATE GOVERNANCE 10 EXECUTIVE AND DIRECTOR COMPENSATION 17 EQUITY COMPENSATION PLAN INFORMATION 20 PAY VERSUS PERFORMANCE 25 REPORT OF AUDIT COMMITTEE 28 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 29 PROPOSALS TO BE VOTED UPON BY HOLDERS OF COMMON STOCK 30 PROPOSAL 1: ELECTION OF CLASS 3 DIRECTORS 30 PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 31 PROPOSAL 3: AMENDMENT TO 2018 EQUITY INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE FOR THE GRANT OF AWARDS BY 160,000 SHARES 33 PROPOSAL 4: ADVISORY VOTE ON APPROVAL OF EXECUTIVE COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT 39 CODE OF CONDUCT AND ETHICS 41 OTHER MATTERS 41 STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR 41 APPENDIX A: 2018 EQUITY INCENTIVE PLAN, AS AMENDED A-1 i TABLE OF CONTENTS Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, New Jersey 07922 PROXY STATEMENT FOR CYCLACEL PHARMACEUTICALS, INC. 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 21, 2024 This proxy statement, along with the accompanying notice of the 2024 annual meeting of stockholders, contains information about the 2024 annual meeting of stockholders of Cyclacel Pharmaceuticals, Inc., including any adjournments or postponements of the annual meeting. This year's annual meeting will be held via live audio webcast on the internet. You will be able to participate, vote and submit your questions during the annual meeting by visiting www.virtualshareholdermeeting.com/CYCC2024. You will not be able to attend the annual meeting physically. In this proxy statement, we refer to Cyclacel Pharmaceuticals, Inc. as "Cyclacel," "the Company," "we" and "us." This proxy statement relates to the solicitation of proxies by our Board of Directors for use at the annual m

View Full Filing

View this DEF 14A filing on SEC EDGAR